CO-VELOCITY-GLOBAL
2.9.2020 07:04:13 CEST | Business Wire | Press release
Velocity Global , the leading provider of global expansion solutions, has selected Amsterdam, Netherlands, as the location for its European headquarters. The Denver-based company appointed Sander Poos as managing director of Europe based in Amsterdam.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200901006149/en/
As an International PEO, Velocity Global serves as an Employer of Record for supported employees in countries where clients have not set up a legal entity, enabling companies to compliantly expand internationally in a matter of weeks, and reduce their expansion costs.
“The number of clients expanding in Europe more than doubled this year compared to the same period in 2019,” said Velocity Global founder and CEO Ben Wright. “Even amidst a global pandemic, our growing clients also doubled the number of supported employees onboarded in Europe this year compared to the same period last year. Europe is critically important for both Velocity Global and our clients.”
The uptick in volume supports findings in Velocity Global’s 2020 State of Global Expansion™ report that 41 percent of tech companies in the U.S. and the UK targeted Europe as the most promising market to grow their customer base.
Amsterdam emerged as the natural choice for Velocity Global’s European headquarters as a business-friendly, culturally attractive city for international commerce. The city is geographically adjacent to key markets like Germany, France, and the United Kingdom. This year, in the final months of the Brexit transition, the European Union received approximately 80 percent of the European growth among Velocity Global clients, while the UK remains the top individual country destination.
Velocity Global established its Amsterdam presence in 2018, and now employs more than 30 team members in Europe serving in corporate and client-facing functions including client experience, employee support, operations, compliance, sales, finance, human resources, and legal.
Sander Poos leads Velocity Global’s team throughout Europe, reporting to Chief Operating Officer José Montero. He adds 25 years of experience in sales and operations in the human resources and software-as-a-service (SaaS) sectors. Poos most recently served as managing director of Benelux for Indeed.com, supporting operations in Amsterdam and Brussels as well as Dublin, Ireland. Previously he held leadership positions for companies including Xerox, Adecco, Monster.com, and Telegraaf Media Group.
“Sander brings a breadth of experience in successfully building people-focused business solutions across Europe,” said Montero. “His leadership balances revenue operations with industry-leading customer experience platforms putting people at the heart of his strategy.”
“New supported employees in Europe represent close to half of our global onboardings this year, a 40 percent increase over the first eight months of 2019,” said Poos. “I am excited to lead European growth for Velocity Global and our clients.”
The company's European team supports 19 languages from Europe, the Middle East, Africa, and Asia, contributing to the 36 languages supported worldwide by Velocity Global. Velocity Global has 250 employees located in 14 countries serving thousands of supported employees for clients in over 100 countries.
ABOUT VELOCITY GLOBAL
Velocity Global is the leading provider of global employment solutions that has reinvented the way companies expand overseas. With unrivaled expertise in over 185 countries, Velocity Global delivers end-to-end services and best-in-class support to help companies confidently navigate the entire lifecycle of international business. To ensure a compliant, efficient, and flexible international expansion, Velocity Global provides a comprehensive suite of global services that includes International PEO, Entity Setup and Support, Global Talent Acquisition, Immigration, and Consulting.
ABOUT SANDER POOS
Sander leads Velocity Global’s European team, responsible for the company’s business activities in the region, including all operations functions, customer experience, service delivery, and partner network alignment. He is a Dutch native based at the company’s European regional headquarters in Amsterdam.
Sander applies 25 years of experience in sales and operations in the human resources and software-as-a-service (SaaS) sectors. He most recently served as managing director of Benelux for Indeed.com, supporting operations in Amsterdam and Brussels as well as Dublin, Ireland. Previously, Sander held leadership positions for companies including Xerox, Adecco, Monster.com, and Telegraaf Media Group.
He received dual university degrees in Labor Market Politics and Personnel Policy, and Catholic Teaching from HAS Den Bosch University Holland, and an MBA from the Imperial College Business School in London. In his free time, he enjoys spending time with his family and playing tennis, and serves on the Board of the Dutch Tennis Association.
See biographies for Velocity Global leaders here .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200901006149/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom